上海凱寶(300039.SZ)擬向凱寶銷售增資2000萬元 後者欲收購順捷醫藥100%股權
格隆匯 12 月 11日丨上海凱寶(300039.SZ)公佈,公司於2020年12月10日召開第五屆董事會第一次會議,審議通過了《關於向全資子公司增資暨收購資產的議案》,同意公司向全資子公司上海凱寶醫藥銷售有限公司(“凱寶銷售”、“子公司”或“丙方”)增資2000萬元,增資完成後,凱寶銷售註冊資本將增加至3000萬元,並同意使用2904.27萬元收購上海順捷醫藥有限公司(“順捷醫藥”)100%股權,授權公司及子公司管理層具體辦理相關事宜。
根據公司發展需要,凱寶銷售收購順捷醫藥100%的股權。此次全資子公司資產收購,將有利於公司及子公司把握戰略機會,開拓相關業務市場,推進經營模式的多樣化轉變,為各類產品和市場領域提供專業性銷售、推廣平台,進一步增強公司運營能力,提升核心競爭力,保障公司持續、健康發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.